Ausbiz Capital is now SureStone Capital. Same team, same ABN and AFS authorisations.

ASX: EBREBR Systems, Inc.Health Care

CMS Proposes National Medicare Coverage for EBR WiSE System

CMS has proposed national Medicare coverage for EBR Systems' WiSE System under Coverage with Evidence Development, with a final decision due by February 2027.

By Digifin Pty Ltd · About this coverage

Key Points

  • Proposal published 18 November 2026 under the TCET pathway with Coverage with Evidence Development
  • Would cover traditional Medicare and Medicare Advantage patients if finalised as proposed
  • Covered patients to enrol in the proposed WiSE-CHOICE study for at least 24 months
  • Public comments close 18 December 2026; final decision expected by 16 February 2027
EBR Systems, Inc. (ASX:EBR)

About EBR Systems (ASX:EBR)

EBR Systems, Inc. is a medical device company headquartered in Santa Clara, California, with CHESS Depositary Interests listed on the ASX. It develops and sells the WiSE CRT System, a wireless pacing system for stimulating the left ventricle of the heart, in the United States.

EBR Systems (ASX:EBR) released this because the U.S. Centers for Medicare & Medicaid Services (CMS) has proposed a National Coverage Determination for its WiSE System, a step towards national Medicare reimbursement.

The proposal was published on 18 November 2026 under CMS's Transitional Coverage for Emerging Technologies (TCET) pathway, with coverage under the Coverage with Evidence Development (CED) framework. If finalised as proposed, patients meeting the criteria would be covered through both traditional Medicare and Medicare Advantage plans. Currently, Medicare Advantage patients, whom the company puts at approximately 50% of the Medicare population, need case-by-case approval from regional Medicare Administrative Contractors. Consistent with the FDA-approved indication, proposed coverage includes previously untreatable patients whose coronary sinus lead implantation was unsuccessful or whose implanted lead has been turned off, and high-risk upgrades for patients with existing pacemakers or implantable cardioverter-defibrillators for whom a standard CRT upgrade is inadvisable. Covered patients would be enrolled in the proposed WiSE-CHOICE study, which compares real-world outcomes with standard treatments and tracks survival and heart failure hospitalisations over at least 24 months.

The proposal is not yet effective. Public comments close on 18 December 2026, with a final decision expected by 16 February 2027. The WiSE-CHOICE study is itself only proposed, and the release gives no estimate of revenue impact.

Back to all ASX Company News

Source: EBR Systems, Inc. (ASX:EBR), 20 November 2026. Summary content supplied by Digifin Pty Ltd.

News summary only, not financial advice. It does not consider your objectives, financial situation or needs.

Friday, 20 November 2026

Also summarised today

All ASX Company News
ASX: ASGConsumer Discretionary

Autosports Group Sees H1 FY27 Revenue In Line With Plan

Autosports Group expects H1 FY27 revenue of $1.7 billion to $1.75 billion, with inventory cuts weighing on gross margin before an expected H2 margin uplift.

20 Nov, 8:26 am AEDT
ASX: DURIndustrials

Duratec Wins Santos, Home Affairs and Defence Fuel Contracts

Duratec has won three contracts worth over $200m combined, led by a four-year Santos maintenance deal, plus Yongah Hill and RAAF Base Learmonth fuel works.

20 Nov, 8:21 am AEDT
ASX: KOAConsumer Discretionary

Koala Written Sales Up 35.0% in First 17 Weeks of FY27

The Koala Company says written sales grew 35.0% in constant currency in the 17 weeks to 31 October, with all markets in growth, before its peak trading period.

20 Nov, 9:04 am AEDT
ASX: MC2Materials

Marimaca Reports 102m of 1.00% Cu at Pampa Medina

Marimaca Copper reported Pampa Medina assays including 102m of 1.00% Cu and 5.1g/t Ag in SPRD-21 as central zone drilling nears completion in northern Chile.

20 Nov, 8:37 am AEDT
ASX: MVFHealth Care

Monash IVF Sees FY27 Underlying NPAT Materially Below FY26

Monash IVF expects underlying FY27 NPAT to be materially below FY26 and consensus after the Australian stimulated-cycle market contracted 3.2% in Q1 FY27.

20 Nov, 9:23 am AEDT
ASX: NXTInformation Technology

NEXTDC Upgrades FY27 Revenue and Underlying EBITDA Guidance

NEXTDC raised FY27 guidance to net revenue of A$485m to A$500m and Underlying EBITDA of A$260m to A$275m, and reaffirmed capex of A$4,500m to A$5,000m.

20 Nov, 8:24 am AEDT
ASX: ORNMaterials

Orion Receives US$6.7M First Glencore Prepayment Drawdown

Orion Minerals has received a US$6.7 million first drawdown under its Glencore prepayment, allowing early works at the Prieska Copper Zinc Mine Uppers Mine.

20 Nov, 9:04 am AEDT
ASX: PMEHealth Care

Pro Medicus Signs 10-Year A$128M NYC Health + Hospitals Deal

Pro Medicus subsidiary Visage Imaging has signed a 10-year, A$128M contract to roll out its cloud-based Visage 7 platform across NYC Health + Hospitals.

20 Nov, 8:27 am AEDT
ASX: SGMMaterials

Sims Lifts 1H FY27 Lifecycle Services EBIT Guidance

Sims expects 1H FY27 Group Underlying EBIT of $270 million to $285 million after lifting Sims Lifecycle Services guidance to $120 million to $130 million.

20 Nov, 8:19 am AEDT

Announcement summaries are published each trading day. General advice only.

Copyright © 2026 SureStone Capital